ELONOX HP SOLUTION

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

ENOXAPARIN SODIUM

から入手可能:

FRESENIUS KABI CANADA LTD

ATCコード:

B01AB05

INN（国際名）:

ENOXAPARIN

投薬量:

120MG

医薬品形態:

SOLUTION

構図:

ENOXAPARIN SODIUM 120MG

投与経路:

INTRAVENOUS

パッケージ内のユニット:

15G/50G

処方タイプ:

Prescription

製品概要:

Active ingredient group (AIG) number: 0131860002; AHFS:

認証ステータス:

APPROVED

承認日:

2022-10-26

製品の特徴

_Product Monograph Master Template _
_Template Date: September 2020 _
_ELONOX and ELONOX HP, (enoxaparin sodium) _
_Page 1 of 81_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
ELONOX
Enoxaparin sodium
Solution for Injection, 100 mg/mL, Subcutaneous or Intravenous Use
30 mg/0.3 mL
40 mg/0.4 mL
60 mg/0.6 mL
80 mg/0.8 mL
100 mg/mL
Pre-filled syringes
PR
ELONOX HP
Enoxaparin sodium
Solution for Injection, 150 mg/mL, Subcutaneous or Intravenous Use
120 mg/0.8 mL
150 mg/mL
Pre-filled syringes
USP
ATC Code: B01AB05
Anticoagulant/Antithrombotic Agent
Fresenius Kabi Canada Ltd.
165 Galaxy Blvd, Suite 100
Toronto Ontario
Canada M9W 0C8
Date of Initial Authorization:
October 26, 2022
Submission Control Number: 243026
_Product Monograph Master Template _
_Template Date: September 2020 _
_ELONOX and ELONOX HP, (enoxaparin sodium) _
_Page 2 of 81_
RECENT MAJOR LABEL CHANGES
N/A
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
...................................................................................................................
4
1.2
Geriatrics
...................................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
5
4
DOSAGE AND ADMINISTRATION
.................................................................................
5
4.1
Dosing Considerations
..............................